Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921618 | 0.81 | MPO (0.51) | MPOMAPK1ALDH1A1L3MBTL1ESR2 | |
| SCHEMBL1921110 | 0.81 | CNR2 (0.48) | MPOLMNATSHR | |
| SCHEMBL29043091 | 0.81 | CNR2 (0.48) | MPOLMNATSHR | |
| SCHEMBL1921321 | 0.81 | MPO (0.50) | MPOMAPK1ALDH1A1L3MBTL1ESR2 | |
| SCHEMBL1920947 | 0.80 | MPO (0.47) | MPOMAPK1ALDH1A1L3MBTL1MYC | |
| SCHEMBL1921546 | 0.79 | MPO (0.49) | MPOMAPK1ALDH1A1L3MBTL1NR4A3 | |
| SCHEMBL29028700 | 0.78 | MPO (0.47) | MPOMAPK1ALDH1A1L3MBTL1ESR2 | |
| SCHEMBL1921361 | 0.78 | MPO (0.47) | MPOALDH1A1NR4A3ESR2LMNA | |
| SCHEMBL28748703 | 0.77 | MEN1 (0.41) | MPOALDH1A1NR4A3ESR2LMNA | |
| SCHEMBL12534013 | 0.77 | MPO (0.47) | MPOMAPK1ALDH1A1L3MBTL1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-9822118-B2 | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | MPO 1730/4885MAPK1 4396/4885ALDH1A1 1020/4885 |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | MPO 1473/4885MAPK1 3348/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.